Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem

Fineline Cube May 14, 2026
Drug

Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations

Fineline Cube May 14, 2026
Company Drug

Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability

Fineline Cube May 14, 2026
Company Drug

CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial

Fineline Cube Apr 23, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial...

Company Drug

CANbridge Pharmaceuticals’ CAN008 Fails to Meet Phase II Endpoints in Glioblastoma Multiforme

Fineline Cube Apr 23, 2024

CANbridge Pharmaceuticals (HKG: 1228) has announced that its Phase II clinical study for CAN008 (asunercept)...

Company Deals R&D

Shenzhen Wingor Biotechnology Partners with Guangzhou Institute of Respiratory Health for MSC Exos Research

Fineline Cube Apr 23, 2024

Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research...

Company Deals

Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software

Fineline Cube Apr 23, 2024

Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic...

Company Drug

GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti

Fineline Cube Apr 23, 2024

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment

Fineline Cube Apr 23, 2024

French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of...

Company

Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released...

Company Deals

Genrix Biopharmaceutical Partners with China Resource Medicine for Expanded Market Coverage

Fineline Cube Apr 23, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a...

Company Deals

Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture

Fineline Cube Apr 23, 2024

Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...

Company

GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues...

Company Deals

Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access

Fineline Cube Apr 23, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a...

Company

Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits

Fineline Cube Apr 23, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as...

Policy / Regulatory

China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration

Fineline Cube Apr 23, 2024

The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...

Company Deals

MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies

Fineline Cube Apr 22, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a...

Company Drug

Jiangsu Hengrui’s SHR-A2102 Earns FDA Fast Track Status for Urothelial Carcinoma Treatment

Fineline Cube Apr 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company Drug

Hengrui Pharmaceuticals Gets Green Light from NMPA for Two Anti-Cancer Drugs

Fineline Cube Apr 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company

Bayer CEO Joins German Chancellor on China Visit, Announces New Investments

Fineline Cube Apr 22, 2024

Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company...

Company Drug

GSK’s Gepotidacin Shows Non-Inferior Efficacy in Phase III Gonorrhoea Tria

Fineline Cube Apr 22, 2024

GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK), a leading UK pharmaceutical company, last week announced positive...

Company Drug

Joincare Pharmaceutical’s TG-1000 Shows Promise in Phase III Flu Treatment Trial

Fineline Cube Apr 22, 2024

Joincare Pharmaceutical Group Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has reportedly completed the...

Company Legal / IP

Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development

Fineline Cube Apr 22, 2024

Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical...

Posts pagination

1 … 371 372 373 … 665

Recent updates

  • Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations
  • Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability
  • TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections
  • Kanghong Pharma’s Gene Therapy KHN921 Receives FDA Approval for Hypertrophic Cardiomyopathy Trial – AAV9 Vector Targets MYBPC3 Mutations with Potential One-Time Treatment
  • InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial – Novel Oral IL-17AA/AF Inhibitor Shows Promise for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug

Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations

Company Drug

Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Company Drug

Kanghong Pharma’s Gene Therapy KHN921 Receives FDA Approval for Hypertrophic Cardiomyopathy Trial – AAV9 Vector Targets MYBPC3 Mutations with Potential One-Time Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.